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Objectives: Resistance-associated variants (RAVs) in Rv0678, a regulator of the MmpS5-MmpL5 efflux pump,
have been shown to lead to increased MICs of bedaquiline (2- to 8- fold) and clofazimine (2- to 4-fold). The
prevalence of these Rv0678 RAVs in clinical isolates and their impact on treatment outcomes are important fac-
tors to take into account in bedaquiline treatment guidelines.
Methods: Baseline isolates from two bedaquiline MDR-TB clinical trials were sequenced for Rv0678 RAVs and cor-
responding bedaquiline MICs were determined on 7H11 agar. Rv0678 RAVs were also investigated in non-MDR-
TB sequences of a population-based cohort.
Results: Rv0678 RAVs were identified in 23/347 (6.3%) of MDR-TB baseline isolates. Surprisingly, bedaquiline
MICs for these isolates were high (>0.24 mg/L, n¼8), normal (0.030.24 mg/L, n¼11) or low (<0.03 mg/L, n¼4).
A variant at position11 in the intergenic regionmmpS5–Rv0678was identified in 39 isolates (11.3%) and appeared
to increase the susceptibility to bedaquiline. In non-MDR-TB isolates, the frequency of Rv0678 RAVs was lower (6/
852 or 0.7%). Competition experiments suggested that rifampicin was not the drug selecting for Rv0678 RAVs.
Conclusions: RAVs in Rv0678 occur more frequently in MDR-TB patients than previously anticipated, are not associated
with prior use of bedaquiline or clofazimine, and in the majority of cases do not lead to bedaquiline MICs above the provi-
sional breakpoint (0.24 mg/L). Their origin remains unknown. Given the variety of RAVs in Rv0678 and their variable ef-
fects on the MIC, only phenotypic drug-susceptibility methods can currently be used to assess bedaquiline susceptibility.
Introduction
Resistance-associated variants (RAVs) that lead to increased MICs of
bedaquiline have been described in three genes of Mycobacterium tu-
berculosis: atpE, Rv0678 and pepQ.1–6 RAVs in atpE, a gene coding for a
transmembrane protein of the ATP synthase, target of bedaquiline,
lead to 8- to 133- fold increases in bedaquiline MIC and have been iso-
lated in vitro upon exposure to bedaquiline, but they have so far not
been observed in clinical isolates from patients treated with bedaqui-
line.7 RAVs in pepQ, leading to 4-fold increases in bedaquiline and clo-
fazimine MICs, have been isolated from mice treated with bedaquiline.
RAVs in Rv0678, a gene regulating the expression of the MmpS5-
MmpL5 efflux pump, lead to 2- to 8- fold increases in bedaquiline MIC
and 2- to 4-fold increases in clofazimine MIC.1 They have been isolated
in vitro upon exposure to clofazimine3 or bedaquiline,1 and have also
been observed in some post-baseline isolates of patients treated with
bedaquiline.7 Although RAVs in Rv0678 lead to increased MICs of
clofazimine, it is not clear whether the use of clofazimine in TB patients
can select for these mutants. The prevalence of these Rv0678 RAVs in
clinical isolates and their impact on bedaquiline MICs and treatment
outcomes are important factors to take into account in bedaquiline
treatment guidelines. Upon the surprising discovery of an Rv0678 RAV
in a baseline isolate from a patient without documented prior use of
clofazimine or bedaquiline, we studied the prevalence of these RAVs in
clinical isolates of MDR-TB and non-MDR-TB patients.
Materials and methods
MDR clinical isolates
Baseline (day 1) M. tuberculosis isolates from participants in Phase 2b stud-
ies C2088 and C2097 were included. On day 1 there were 374 isolates avail-
able, of which 363 had bedaquiline MICs available, and, out of these, DNA
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was available for 359 isolates (96%), which had their Rv0678 gene
sequenced. Only seven of these patients had documented prior use of
bedaquiline of clofazimine in their medical history.
Susceptibility testing
Bedaquiline MICs for C208 and C209 MDR-TB isolates were determined on
Middlebrook 7H11 agar at 0.004, 0.008, 0.015, 0.03, 0.06, 0.12, 0.24, 0.48,
1.0, 2.0, 4.0 and 8.0 mg/L as described previously.9 Each new batch of 7H11
medium had the H37Rv reference strain (BCCM/ITM 083715) tested as
quality control, with an acceptable MIC range of 0.03–0.12 mg/L. The MIC
was determined as the lowest concentration of the antibiotic that resulted
in 99% growth inhibition.
Susceptibility of BCA8, an H37Rv-derived Rv0678 mutant,1 to TB drugs
other than pyrazinamide was determined in 7H9 broth by the resazurin
microtitre assay (REMA) as previously described.10 The percentage of
growth in each well was calculated using the fluorescence of the growth
control minus the fluorescence of the non-growth control as 100% growth.
The MIC50 was defined as the lowest concentration of antibiotic that re-
sulted in 50% inhibition of growth. The average of the MIC50s was taken
after log transforming all individual MIC50s, including the censored ones.
The censor added to the average was based on the relative occurrence of
the censor in the individual data. When the censor occurred in less than
one-third of the data, the censor was omitted. When the censor occurred in
more than two-thirds of the data, the censored was added to the average.
When the censor occurred between one-third and two-thirds of the data
the censored was used but an equals sign was added. To calculate the sig-
nificance of the fold change, a one-sided unpaired t-test was performed
with unequal variance. Pyrazinamide resistance testing was done using the
MGIT-PZA kit (Becton Dickinson) as per the manufacturer’s instructions.
Rv0678, atpE and pepQ sequencing
A DNA fragment containing Rv0678 and part of the intergenic region be-
tween mmpS5 and Rv0678 of C208 and C209 MDR-TB isolates was ampli-
fied by PCR using primers CV010 and CV017 or 916R20 and 30F22 (Table S1,
available as Supplementary data at JAC Online). The atpE and pepQ
genes were amplified using primers atpEforward with atpEreverse, and
pepQforward with pepQreverse, respectively, (Table S1) in the eight base-
line isolates with MICs above the breakpoint (>0.24 mg/L).11 The PCR prod-
ucts sequenced with the same primers used for amplification. For analysis
of the sequences, Rv0678 sequence from M. tuberculosis H37Rv was taken
as a reference12 (http://tuberculist.epfl.ch).
Data mining of non-MDR clinical isolates
A total of 941 isolates from the Hamburg non-MDR-TB cohort13 were mined
to look for mutations in the same region. These samples were isolated be-
tween 2004 and 2012 and sequenced using the Illumina platforms with
read lengths of 100 bp. SNP calling was undertaken using the Snippy v2.914
pipeline, which employs BWA (read-quality cleaning and mapping
functions), SAMtools and FreeBayes. The genome of strain H37Rv (NC-
000962.3) was used as a reference. Drug resistance and lineage assign-
ment was determined from the genomes using the PhyResSE resistance list
version 27.15
TB lineage analysis
TB lineage analysis for the clinical trial isolates was done by a real-time PCR
assay targeting lineage-specific SNPs as described by Stucki et al.16 with
modified probes and primers for lineage 2 (Table S2). Isolates with an un-
clear SNP profile were tested by spoligotyping using the MIRU-VNTRplus on-
line application (http://www.miru-vntrplus.org/MIRU/index.faces).
Competition experiments
Two M. tuberculosis H37Rv-derived strains were used: H37Rv-rpoB, carrying
a mutation in the rpoB gene (H526Y); and CV37-rpoB, carrying mutations in
rpoB (H526Y) and Rv0678 (IS6110 nt 104). These strains were transformed
with pND235,17 a plasmid containing green fluorescent protein (GFP) (kem
475 nm, kex 525 nm), and pND239,18 a plasmid containing DsRed2 (kem
575 nm, kex 632 nm), in order to generate fluorescence-marked strains
(Table S1). To rule out any effect of the plasmids on the fitness of bacteria,
competition experiments were done in two pairs: H37Rv-rpoB-pND235 (GFP
marked) with CV37-rpoB-pN239 (DsRed2 marked); and H37Rv-rpoB-
pND239 (DsRed2 marked) with CV37-rpoB-pN235 (GFP marked).
Competition experiments were adapted from Gullberg et al.19 Cultures
were grown in 7H9/10% OADC/0.05% Tween broth to the logarithmic
phase and diluted to OD¼0.1. These were further diluted 1:200 to obtain a
final bacterial inoculation density of 5104 cfu/mL per strain. Two inde-
pendent flasks were inoculated with: (i) H37Rv-rpoB-pND235 and CV37-
rpoB-pND239; and (ii) H37Rv-rpoB-pND239 and CV37-rpoB-pND235.
Aliquots (5 mL) from each culture were put in 10 flasks; rifampicin was
added to 8 of them (concentrations: 200, 100, 50, 25, 12.5, 6.25, 0.625 and
0.0625 mg/L) and 2 remained antibiotic-free. After incubation for 1 week at
37 C, a 500 lL aliquot from all cultures was washed with 200 lL of PBS,
inactivated for 90 min at 4 C in 400 lL of 4% paraformaldehyde20 and fi-
nally resuspended in 200 lL of PBS. Serial decimal dilutions were analysed
using a fluorescence-activated cell sorter in an FACS Fortessa. A minimum
of 104 cells were counted per sample. The percentages of GFP-containing
and DsRed2-containing bacilli were determined in each sample and the
ratio of CV37-rpoB to H37Rv-rpoB was calculated for each condition. On the
same day, every culture was passaged at a dilution of 1:1000 to a new flask
containing the same concentration of rifampicin. These steps of sampling
and passage were repeated every week for 3 weeks.
Results
MDR-TB clinical isolates at baseline contain RAVs in
Rv0678, not always linked to high bedaquiline MICs
Interpretable Rv0678 sequencing results and bedaquiline MICs were
available for 347 out of 359 investigated baseline isolates from
MDR-TB isolates (Table 1). Their MICs ranged from 0.004 to
1.0 mg/L, with a mean MIC of 0.06 mg/L. The majority (296/347,
85.3%) had normal MICs (0.03–0.24 mg/L) (typically seen for the
H37Rv reference strain), a smaller proportion (43/347, 12.4%) had
low MICs (0.015 mg/L) and 8/347 (2.3%) isolates had an MIC
>0.24 mg/L, the provisional breakpoint for bedaquiline on 7H11
agar.11
An overview of all the Rv0678 RAVs is presented in Figure 1 and
Table S3. The higher MICs could all be explained by RAVs in Rv0678
– no RAVs were found in atpE or pepQ genes of these isolates.
However, 15 additional baseline isolates (4.3%) had similar
Rv0678 RAVs that did not result in a high bedaquiline MIC. Taken
together, 6.6% (95% CI 4.0%–9.2%) of MDR-TB baseline isolates
had an RAV in the Rv0678 coding sequence. Rv0678 RAVs were not
identified in any of the seven patients that had failed previous ther-
apy with a regimen containing clofazimine prior to enrolment in
the bedaquiline trial.
Intergenic mutations at positions 44 and 59, outside of the
hypothetical binding site of Rv0678 described by Milano et al.21
were observed in<1% of the isolates and were not associated
with high bedaquiline MICs. Intergenic mutations at position 11
were observed in 39 out of the 347 isolates (11%); in 2 out of 39
this mutation appeared simultaneously with another non-silent
RAV in Rv0678. The 37 isolates with only a mutation at position
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11 were associated with low to moderate bedaquiline MICs
(mean MIC 0.015 mg/L). An IS6110 insertion at position 13
in the intergenic region was present in combination with a mis-
sense mutation in Rv0678 in one isolate with a high MIC. The
heterogeneous nature of clinical isolates explains why in some
cases mixtures of WT sequences and RAVs were observed (nine
isolates, 2.6%). Silent mutations in Rv0678 were observed in 1% of
the isolates.
Table 1. MICs for and mutations of MDR-TB baseline clinical isolates
Rv0678 locus
Number of isolates with bedaquiline MIC (mg/L)
Total1.000 0.480 0.240 0.120 0.060 0.030 0.015 0.007 0.004
Non-silent mutation 1 5 2 3 1 1 13
WTþnon-silent mutation 1 1 3 1 6
WTþnon-silent mutationþmutation in position11 2 2
WTþnon-silent mutationþ silent mutation 1 1
Non-silent mutationþmutation in position13 1 1
Intergenic mutation in position11 or intergenic
mutation in position11þ Rv0678 silent mutation
7 28 2 37
Intergenic mutation, not11 1 1 2
Silent mutations or mixture of WTþ silent 1 2 1 4
WT 2 48 153 69 7 2 281
Total analysed 2 6 5 53 160 78 37 1 5 347
The numbers of isolates with high (>0.24 mg/L), normal (0.03–0.24 mg/L) and low (<0.03 mg/L) bedaquiline MICs are indicated for every type of
mutation in the Rv0678 gene and the intergenic region mmpS5–Rv0678 .
Non-silent mutations refer to non-synonymous mutations and small insertions or deletions in the Rv0678 coding region.
Figure 1. Mutations in Rv0678 and the intergenic region mmpS5–Rv0678 and lineage of their respective isolates. All the different DNA mutations
found in C208 and C209 baseline isolates (MDR, purple markers) and in the Hamburg cohort (non-MDR, orange markers) are shown. Silent mutations
are not shown. Mutations in isolates with high MICs are coloured in pink. The circle next to every mutation indicates the lineage of the isolate: blue,
lineage 1; red, lineage 2; yellow, lineage 3; and green, lineage 4. When the mutation was found in more than one isolate, the number of isolates car-
rying that mutation is indicated in brackets. Some isolates carry more than one mutation, and the mutations found in the same isolate are indicated









niversity of Bradford user on 24 O
ctober 2019
To investigate whether the presence of Rv0678RAVs at baseline
was associated with a specific lineage of M. tuberculosis, the pres-
ence of lineage-specific SNPs was analysed.16 The majority of the
isolates belonged to lineage 2 (167/347, 48.1%) and lineage 4
(159/347, 45.8%), and only a few to lineage 1 (13/347, 3.7%) and
lineage 3 (8/347, 2.3%). Baseline isolates carrying Rv0678 RAVs,
including the intergenic region, were more abundant in lineage 2
(54/167, 32.3%). Interestingly, all the isolates containing the same
mutation at position 11 in the intergenic region mmpS5–Rv0678
belonged to the Beijing family of lineage 2, which suggests that all
these might be phylogenetically close. Out of the 54 isolates with
Rv0678 RAVs, 19 contained a missense mutation or an intergenic
mutation different from 11 C!A in Rv0678, either alone or in a
mixture. Rv0678 RAVs were less frequent in lineage 3 (1/8, 12.5%)
and lineage 4 (7/159, 4.4%). None of the 13 isolates belonging to
lineage 1 had Rv0678 RAVs.
Out of the eight isolates with high baseline MICs (>0.24 mg/L),
five belonged to lineage 2 and three belonged to lineage 4. Low
bedaquiline MICs were more frequent in lineage 2 (34/43) and nor-
mally associated with the Rv0678 RAV in position11.
Non-MDR-TB isolates
Sequencing data were available for 941 isolates from non-MDR-TB
patients of the Hamburg cohort. Read depth coverage resulting
from mapping to the reference H37Rv genome averaged at 154
(range 34 to 740) across isolates. Based on genomic SNP data,
852 isolates (90.5%) were pan-susceptible to all drugs included
in the PhyResSE resistance list (fluoroquinolones, ethionamide,
rifampicin, streptomycin, linezolid, amikacin, kanamycin, cipro-
floxacin, isoniazid, pyrazinamide, p-aminosalicylic acid and eth-
ambutol). Isolates with predicted drug resistance were usually
resistant to isoniazid (66 isolates). Six isolates had RAVs in Rv0678
(0.7% prevalence, 95% CI 0.1%–1.2%), although no other drug re-
sistance was detected in these isolates. These isolates were not
clustered in a transmission chain (i.e.>12 SNPs from each other22)
and were from lineages 1 (2/54 isolates), 3 (2/65 isolates) and 4
(2/704 isolates) (Figure 1).
Cross-resistance of Rv0678 mutants with other TB drugs
and potential selection pressures
The high prevalence of Rv0678 RAVs in baseline samples from pa-
tients without prior treatment with bedaquiline or clofazimine sug-
gests that there is selection pressure favouring Rv0678 RAVs. The
fact that many Rv0678 RAVs are present in a mixture with WT
Rv0678 suggests that this selection pressure is mild, which is in ac-
cordance with a moderate fold increase in the MIC of the drug. We
determined the susceptibility of BCA8, an Rv0678 mutant strain
derived from H37Rv,1 to a panel of first- and second-line TB drugs
to identify additional cross-resistance with bedaquiline via the
same mechanism (Table 2). Bedaquiline and clofazimine had
increased MICs for the Rv0678 mutant strain. Telithromycin and ri-
fampicin also displayed slightly increased MICs for the Rv0678mu-
tant (5- and 3-fold, respectively), although the results were not
statistically significant. We hypothesized that Rv0678 RAVs, lead-
ing to overexpression of the MmpL5 efflux pump, could benefit
the survival of MDR strains in the presence of rifampicin (see the
Discussion section). To test this hypothesis, we looked at the
competitive advantage of the double mutant Rv0678-rpoB over
the single rpoB mutant in the presence of different concentrations
of rifampicin (ranging from 0.06 to 200 mg/L) through several gen-
erations. If the double mutant had a competitive advantage in the
presence of rifampicin, then this population would be enriched in
every generation. As can be observed in Figure S1, we found the
opposite effect: the population of the double mutant Rv0678-rpoB
decreased in every passage. Rifampicin is apparently not able to
select for Rv0678 RAVs in an rpoB mutant background, and is
therefore unlikely to be responsible for the higher prevalence of
Rv0678 RAVs in MDR baseline isolates.
Discussion
Of the MDR-TB isolates, 2.3% (8/347) had bedaquiline MICs
>0.24 mg/L. All high baseline MICs could be explained by RAVs in
Rv0678, and none of these isolates had an RAV in atpE or pepQ.
RAVs in Rv0678 were not only identified in isolates with high base-
line MICs: 4.3% of the isolates had similar RAVs (some with inser-
tions or deletions), not resulting in bedaquiline MICs exceeding the
bedaquiline breakpoint, suggesting a role of additional genes in
determining the bedaquiline MIC. In total, RAVs in Rv0678 were
observed in 6.6% of the MDR-TB isolates and they were associated
with bedaquiline MICs exceeding the breakpoint in only 1 out of 3
cases (8 out of 23).
Intergenic mutations were observed in<1% of the isolates and
generally were not associated with high bedaquiline MICs. RAVs in
the intergenic region between Rv0678 and mmpS5 at positions9
and 10 in the hypothetical binding site of Rv0678 were previ-
ously shown to increase the expression of the MmpL5 efflux
pump.21 Only one mutation was found at this binding site, and it
was combined with another mutation in the gene itself, both prob-
ably contributing to the high bedaquiline MIC for the isolate. RAVs
at44 and59, outside of the Rv0678 binding site, were identified
in<1.0% of the isolates, but did not result in high bedaquiline MICs
(0.06–0.24 mg/L). RAVs at intergenic position 11 have not been
described before and were observed in 10.7% of the 347 MDR-TB
isolates in our sample. Interestingly, RAVs at this position were
only observed in isolates from (several locations in) South Africa
and they all belong to the W-Beijing lineage. They were associated
with low to moderate bedaquiline MICs (0.004–0.03 mg/L, mean
MIC 0.015 mg/L).
In 2.6% of the isolates we found a mixture of WT and mutant
Rv0678. Mixtures could be the result of either spontaneous muta-
tions that were further selected, or a mixed infection with two
strains. Since the Sanger sequencing technique does not provide
this information, we performed MIRU-VNTR typing for the mixtures
and found no evidence of mixed infection, so the Rv0678 mutants
were a subpopulation that was selected within the patient.
The prevalence of Rv0678 RAVs in pan-susceptible TB isolates
from the population-based Hamburg cohort was 9-fold lower
compared with the MDR-TB cohort, with only 6 sequences out of
the 852 (0.7%) having a polymorphism in Rv0678. Bedaquiline
MICs were not available for this data set.
The high prevalence of Rv0678 RAVs in baseline isolates of MDR-
TB patients is surprising, given that none of these patients had
been exposed to bedaquiline; nor was there any evidence for prior
use of clofazimine in these patient’s medical histories (except for
seven subjects). Although one cannot exclude that some of these
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patients were originally infected with strains already resistant to
clofazimine, several factors argue against this possibility. Firstly,
Rv0678 RAVs were not identified in any of the seven patients that
had failed previous therapy with a regimen containing clofazimine
prior to enrolment in the bedaquiline study. Secondly, the preva-
lence of Rv0678 RAVs was not higher in treatment-experienced
MDR-TB patients or in pre-XDR- and XDR-TB patients.
Overall, Rv0678 RAVs lead to low-level resistance, and the ef-
fect on treatment outcome is not clear. Several letters and papers
reported on a single patient developing an Rv0678 RAV while fail-
ing bedaquiline therapy and suggested a causal link between the
RAV and the treatment failure,23–25 but in a clinical trial 12 patients
whose isolates had acquired an Rv0678 RAV at the interim analysis
were as likely to have converted at endpoint as those that had not
developed an Rv0678 RAV.7 Although these data are limited, they
do not suggest that increases in bedaquiline MICs on treatment
and due to Rv0678 RAVs have a negative effect on treatment re-
sponse. There was also no clear relationship between bedaquiline
baseline MIC and culture conversion at the endpoint, although
more efficacy data are needed for patients with baseline MICs
above the provisional breakpoint. Efficacy studies in a mouse
model of TB infection indicate that bedaquiline treatment is still
bactericidal for such isolates, although to a lesser extent compared
with the effect seen when treating an isolate without an Rv0678
RAV.1
The much lower frequency of Rv0678 RAVs in sequences from
non-MDR-TB patients suggests a role of prior exposure to TB drugs.
As all RAVs described in this article were isolated from patients
prior to the introduction of bedaquiline, prior exposure to clofazi-
mine was the most obvious hypothesis to explain their origin.
However, none of the seven patientswith prior documented use of
clofazimine in this study had developed RAVs in Rv0678, and use of
clofazimine in patients has not yet been reported to select for
Rv0678 RAVs by other investigators. In view of these findings, prior
exposure to clofazimine should not automatically lead to exclusion
of bedaquiline treatment. Rv0678 RAVs did not occur more fre-
quently in treatment-experienced MDR-TB isolates or in isolates
from pre-XDR- or XDR-TB patients, providing further evidence
against a role of clofazimine.
To rule out that other TB drugs than clofazimine were respon-
sible for the selection of Rv0678 RAVs, an H37Rv isolate susceptible
to first- and second-line anti-TB drugs, yet overexpressing the
Table 2. MIC50s of a panel of first- and second-line TB drugs for H37Rv and BCA8
Compound
MIC50 (mg/L) (n)
Fold change in MIC50 BCA8/H37Rv PH37Rv BCA8
Bedaquiline base 0.04 (11) 0.31 (10) 7.77* <0.0004
Bedaquiline fumarate 0.04 (6) 0.28 (5) 6.74* <0.0004
Clofazimine 0.11 (7) 0.38 (5) 3.52* <0.0008
Thioridazine 6.44 (6) 10.09 (2) 1.57* 0.04084
Telithromycin 2.28 (7) 11.26 (5) 4.94 >0.05
Rifampicin 0.01 (13) 0.02 (10) 2.86 >0.05
Amoxicillin/clavulanic acid 2/1 5.73 (6) 9.61 (4) 1.68 >0.05
Rifapentin 0.005 (7) 0.01 (5) 1.57 >0.05
Ethambutol 1.81 (7) 2.38 (5) 1.31 >0.05
Moxifloxacin 0.07 (7) 0.08 (5) 1.24 >0.05
Erythromycin 5.26 (7) 6.36 (5) 1.21 >0.05
Clarithromycin 0.6 (12) 0.66 (10) 1.09 >0.05
Rifabutin 0.003 (6) 0.003 (2) 1.01 >0.05
Amikacin 0.39 (6) 0.36 (5) 0.93 >0.05
Ofloxacin 0.32 (7) 0.29 (5) 0.92 >0.05
Terizidone 4.32 (6) 3.76 (2) 0.87 >0.05
Levofloxacin 0.22 (13) 0.18 (10) 0.79 >0.05
Linezolid (batch 2) 0.37 (7) 0.29 (5) 0.78 >0.05
Capreomycin 0.61 (7) 0.45 (5) 0.74 >0.05
Linezolid (batch 1) 0.47 (6) 0.30 (5) 0.62 >0.05
p-Aminosalicylic acid 0.02 (7) 0.01 (5) 0.5 >0.05
Streptomycin 0.33 (6) 0.16 (2) 0.48 >0.05
Isoniazid 0.12 (7) 0.05 (4) 0.46 >0.05
Protionamide 2.11 (5) 0.82 (1) 0.39 >0.05
The MIC50s for the WT (H37Rv) and an Rv0678 mutant (BCA8) are shown.
The number of times that the compound was tested is indicated in parentheses.
The MIC50 fold changes are calculated based on unrounded values.
Fold changes based on censored values become themselves censored.
The MIC50 fold changes that are statistically significant (P<0.05) are marked with an asterisk.
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MmpL5 efflux pump, was used to assess any cross-resistance with
a large panel of TB drugs. The only MICs that were significantly
increased (>3-fold, P<0.05) in this strain were those of bedaqui-
line and clofazimine. Rifampicin turned out to be the most suspi-
cious candidate of the list, being a first-line drug with a slightly
increased MIC (2.9-fold) in the mutant overexpressing the efflux
pump. In addition, increased expression of this efflux pump was
described in a rifampicin-resistant (rpoB mutant) strain upon ex-
posure to subinhibitory levels of rifampicin.26 We therefore investi-
gated whether rifampicin could select for Rv0678 mutations in
rpoB mutants by assessing the competitive advantage of the dou-
ble mutant Rv0678-rpoB over the single rpoB mutant, in the pres-
ence of different concentrations of rifampicin. Since the double
mutant did not grow better than the single mutant in the presence
of the drug, rifampicin is unlikely to be responsible for the high
prevalence of Rv0678 RAVs in MDR-TB baseline isolates.
The natural function of MmpS5/MmpL5 efflux pumps is to export
siderophores.27 Expression of the efflux pump is down-regulated in
high iron conditions,28 and one can expect up-regulation in low iron
conditions. We checked whether the prevalence of Rv0678 RAVs
was higher in isolates from female patients, but this did not appear
to be the case. Iron-limiting conditions are also thought to exist in
granulomatous lesions of TB. The origin of these ‘naive’ Rv0678
RAVs is therefore elusive at this point in time.
There was no evidence for Rv0678 RAVs being linked to specific
TB lineages, as they were observed in lineages 2, 3 and 4. In con-
trast, RAVs in the intergenic region at position11 were exclusively
observed in W-Beijing isolates.
Our study has several implications for bedaquiline DST develop-
ment. The absence of an algorithm to predict bedaquiline MICs
based on specific Rv0678 RAVs limits the value of sequencing this
specific gene—RAVs in Rv0678 were associated with bedaquiline
MICs exceeding the breakpoint in only 8 out of 23 cases. Sequencing
Rv0678 could be useful to rule out resistance to bedaquiline, but not
to rule in resistance. Phenotypic DST tests remain the method of
choice to monitor bedaquiline susceptibility
The prevalence of high baseline MICs of bedaquiline in 2.3% of
patients without prior exposure to bedaquiline or clofazimine is
worrisome and further surveillance studies are required to explain
their origin, and to generate more data on their impact on treat-
ment outcomes. The frequency of target-based (atpE) and non-
target-based (Rv0678) RAVs for bedaquiline was similar in a set of
in vitro selected isolates,4 but the latter are more likely to emerge
first, as efflux-based mutations generally lead to lower levels of re-
sistance (2- to 16-fold higher MICs) than target-based mutations
(16- to 1000-fold higher MICs). This increases the likelihood that
non-target-based resistance will be used as a stepping stone even-
tually leading to higher-level, target-based resistance in patients
on a failing treatment regimen.
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